Tubulovillous adenoma with high-grade dysplasia of the vulva harboring high tumor mutational burden and cancer-associated mutations: a case report.

A 63-year-old Japanese woman, gravida 4, para 3, was aware of a mass in the vulva and visited the clinic. She has no medical or family history and no smoking history. There was a 1 cm mass on the vulva that had self-destructed. Biopsy revealed a dysplastic glandular neoplasm (Fig.  1 A), and the histopathological diagnosis was adenocarcinoma. The pathological findings were not typical for vulvar primary cancer, and metastatic carcinoma of gastrointestinal origin was suspected. The patient was referred to our hospital. Fig. 1 MRI and visual findings (after biopsy). A Hematoxylin–eosin staining of the biopsy specimen. Magnification: 100 × , scale bar: 250 µm. B Visual findings. There was a red lesion at the vaginal entry at 7 o'clock (black arrowhead). C MRI T2-weighted image (axial). The lesion showed a high signal (white arrowhead). D MRI diffusion-weighted image (axial). The lesion showed restricted diffusion (white arrowhead). E Surgical specimen. The thread indicates the ventral direction MRI and visual findings (after biopsy). A Hematoxylin–eosin staining of the biopsy specimen. Magnification: 100 × , scale bar: 250 µm. B Visual findings. There was a red lesion at the vaginal entry at 7 o'clock (black arrowhead). C MRI T2-weighted image (axial). The lesion showed a high signal (white arrowhead). D MRI diffusion-weighted image (axial). The lesion showed restricted diffusion (white arrowhead). E Surgical specimen. The thread indicates the ventral direction Gross findings at the time of the visit to our hospital were redness with ulceration of approximately 5 mm just outside the 7 o'clock remains of the hymen, and the mass had disappeared (Fig.  1 B). On magnetic resonance imaging, no obvious mass was detected on both T1-weighted and T2-weighted images, but on the diffusion-weighted image, there was a high-signal area of approximately 5 mm that was presumed to be a tumor lesion (Fig.  1 C, D). Contrast-enhanced computed tomography and positron emission tomography showed no enlarged lymph nodes or distant metastases. Tumor markers were as follows: CEA, 1.8 ng/mL; CA125, 12 U/mL; and CA19-9, 40 U/mL. Only CA19-9 was slightly elevated. Upper gastrointestinal endoscopy revealed erosions in the gastric angulus, from which one biopsy was performed, but no malignant findings were observed. Lower gastrointestinal endoscopy revealed no abnormal findings. Wide local excision of the vulvar tumor was performed under spinal anesthesia. The resected specimen was 2 × 1 × 1 cm in size with a margin at the site of the probable tumor (Fig.  1 E). Grossly, there was an approximate 5 mm depression in the skin. The operation took 23 min and there was minimal blood loss. The postoperative course was good, and the patient was discharged the day after surgery. Histologic examination revealed that the tumor was situated in the mucosa covered by squamous epithelium, some portion of which had sebaceous glands. The tumor was a cystic lesion invaginating from the surface and was lined by a tubulovillous proliferation of dysplastic columnar epithelium (Fig.  2 A). The nuclei were enlarged, and nucleoli were prominent. The mitotic activity was brisk. There were some fused glands, which were especially apparent in the tissue obtained in biopsy (Fig.  1 A). Some dysplastic glands were on the mucosal surface and continuous with the non-neoplastic squamous epithelium (Fig.  2 A, B). The tumor was well-circumscribed, with no infiltrative growth or lymphovascular infiltration. Sebaceous glands were the only non-dysplastic glandular elements present in the vicinity of the tumor; Skene glands, minor vestibular glands, endometriosis, ectopic intestinal mucosa, and intestinal metaplasia were not identified. A portion of Bartholin gland was in the periphery of the resected specimen, apart from the tumor. Fig. 2 Pathological findings of hematoxylin–eosin staining. A Hematoxylin–eosin staining. A magnified view of the arrowhead is shown in ( B ). The asterisk indicates contamination. Magnification: 12.5 × , scale bar: 1000 µm. B Magnified view of the arrowhead in ( A ). Magnification: 100 × , scale bar: 100 µm Pathological findings of hematoxylin–eosin staining. A Hematoxylin–eosin staining. A magnified view of the arrowhead is shown in ( B ). The asterisk indicates contamination. Magnification: 12.5 × , scale bar: 1000 µm. B Magnified view of the arrowhead in ( A ). Magnification: 100 × , scale bar: 100 µm IHC results were as follows: cytokeratin (CK) 20: positive, CK7: focal positive, CDX2: positive, estrogen receptor (ER): negative, progesterone receptor (PgR): negative, and PAX8: negative (Fig.  3 A–F). p16 expression was strong and diffusely positive (Fig.  3 G), and human papillomavirus (HPV) was negative (Fig.  3 H). p53 was null pattern (Fig.  3 I). PMS2 and MSH6 expressions were detected (Fig.  3 J, K). On the basis of these results, the patient was diagnosed with primary adenocarcinoma of intestinal-type of the vulva. A gene panel test (FoundationOneCDx assay, Foundation Medicine, Inc., Cambridge, MA, USA) was performed on the tumor portion of the explanted specimen. TMB was high, at 13 mutations/megabase (Mut/Mb). The tumor was microsatellite stable. Gene mutations in TP53 , KEL , RB1 , RNF43 , PTEN , GNAS , and PIK3CA were detected (Table 1 ). Fig. 3 Pathological findings of immunohistochemistry. A Cytokeratin 20. Magnification: 100 × , scale bar: 200 µm. B Cytokeratin 7. Magnification: 100 × , scale bar: 200 µm. C . CDX2. Magnification: 100 × , scale bar: 200 µm. D Estrogen receptor. Magnification: 100 × , scale bar: 200 µm. E Progesterone receptor. Magnification: 100 × , scale bar: 200 µm. F PAX8. Magnification: 100 × , scale bar: 200 µm. G p16. Magnification: 100 × , scale bar: 200 µm. H HPV. Magnification: 100 × , scale bar: 200 µm. I p53. Magnification: 100 × , scale bar: 200 µm. J PMS2. Magnification: 100 × , scale bar: 200 µm. K MSH6. Magnification: 100 × , scale bar: 200 µm Table 1 Gene mutations in the tumor specimen detected by FoundationOneCDx Gene Alteration VAF (%) TP53 splice site 672 + 1G > T 67.9 KEL M1T 55.7 RB1 I815fs*11 40.6 RNF43 E258* 36.4 PTEN T319fs*1 23.0 GNAS R201H 1.9 PIK3CA E453K 1.8 Pathological findings of immunohistochemistry. A Cytokeratin 20. Magnification: 100 × , scale bar: 200 µm. B Cytokeratin 7. Magnification: 100 × , scale bar: 200 µm. C . CDX2. Magnification: 100 × , scale bar: 200 µm. D Estrogen receptor. Magnification: 100 × , scale bar: 200 µm. E Progesterone receptor. Magnification: 100 × , scale bar: 200 µm. F PAX8. Magnification: 100 × , scale bar: 200 µm. G p16. Magnification: 100 × , scale bar: 200 µm. H HPV. Magnification: 100 × , scale bar: 200 µm. I p53. Magnification: 100 × , scale bar: 200 µm. J PMS2. Magnification: 100 × , scale bar: 200 µm. K MSH6. Magnification: 100 × , scale bar: 200 µm Gene mutations in the tumor specimen detected by FoundationOneCDx The patient did not receive any adjuvant therapy. At 30 months postoperation, there has been no recurrence.

Vulvar cancer accounts for only approximately 3–4% of gynecologic malignancies [ 1 ]. Approximately 80% of vulvar cancers are squamous cell carcinoma, followed by basal cell carcinoma, Paget's disease, and melanoma; adenocarcinoma is very rare [ 1 ]. Adenocarcinoma of intestinal-type of the vulva was first reported in 1964 [ 2 ] and is diagnosed based on characteristic pathologic findings and immunohistochemistry (IHC). Several theories have been reported regarding the origin of intestinal-type neoplasms of the vulva: the urethra, lower vaginal area, and rectum are derived from the cloaca, so the lower vaginal area contains remnants of bowel tissue [ 3 ]; ectopic bowel epithelium or intestinal metaplasia within the tissue derived from Müllerian duct [ 4 ]; and Bartholin’s glands in the vulva [ 5 ]. The precise origin and the evolution of intestinal-type neoplasms of the vulva remain unknown and there is no established treatment. Additionally, the genetic mutation patterns of intestinal-type neoplasms of the vulva have not been investigated. Here, we report a case of tubulovillous adenoma with high-grade dysplasia of the vulva, as a precancerous lesion of intestinal-type neoplasm of the vulva, with multiple cancer-associated mutations and high tumor mutational burden (TMB).

Thirty cases of adenocarcinoma of intestinal-type of the vulva or vagina have been reported. The cases were reported in a wide range of countries and races, and the mean patient age is 54.1 (31–69) years (Table 2 ) [ 3 – 30 ]. Symptoms of adenocarcinoma of intestinal-type of the vulva include pain, itching, and bleeding. In the early stage of cancer or precancerous lesion, as in the present case, the patient may present only with a mass (Table 2 ). One report suggests that adenocarcinoma of intestinal-type of the vulva may have a poor prognosis and that endoscopic follow-up of the colon is mandatory because of the high tendency to complicate gastrointestinal tumors [ 18 ]. In most cases, however, the clinical courses are gradual, and the prognosis is good (Table 2 ). Table 2 Cases of intestinal-type adenocarcinoma of vulva and vagina Year First Author Country Race Age Symptom Location Maximum tumor size (cm) Operation Adjuvant therapy Stage LN meta Follow (month) Prognosis CK20 CK7 CEA CDX2 p16 ER PR 1978 Tiltman South Africa NA 50 dyspareunia, discharge external urethral meatus 2 RV + LND none II positive 12 NED NA NA - NA NA NA NA 1988 Fox UK NA 35 discharge, bleeding left lateral and anterior viginal wall 5 WLE none NA NA NA NA NA NA NA NA NA NA NA 1991 Mortensen Denmark NA 43 discharge, bleeding posterior rim of hymenal caruncle 1.7 WLE none NA NA 27 rec 23 m: re-resection NA NA  +  NA NA NA NA 1993 Kennedy USA NA 54 vulvar mass left posterior vulva 2 RV + LND none I negative 120 NED  +   +  - NA NA NA NA 1993 Kennedy USA NA 63 none frenulum of labia minor 1.5 WLE none I negative 48 NED NA NA NA NA NA NA NA 1995 Ghamande USA NA 67 bleeding frenulum of labia minor 1.7 RV + LND none I negative 17 NED NA NA  +  NA NA NA NA 1999 Nagar UK NA 36 bleeding anterolateral upper vaginal wall NA WLE NA NA NA NA NA NA NA NA NA NA NA NA 1999 Willen Sweden NA 57 none left posterior vestibule 1 WLE none I negative 26 NED NA NA  +  NA NA NA NA 2001 Mudhar UK NA 56 bleeding, discharge posterior vaginal wall 1 WLE none I negative 12 NED  +  -  +  NA NA NA NA 2001 Zaidi USA African 43 vulvar mass, discomfort, bleeding frenulum of labia minor 5 RV + LND none NA negative 18 NED NA NA  +  NA NA - - 2001 Rodriguez Spain NA 69 vulvar mass, itchy right labia major 1.5 WLE none I negative 36 NED  +   +   +  NA NA - - 2003 Liu Taiwan Asian 49 NA left labia major 2 RV + LND none I negative 24 NED NA NA NA NA NA NA NA 2004 Dube Canada NA 58 vulvar mass, discomfort, burning right labia major 1.5 RV none I negative 16 NED  +   +  NA NA NA - - 2005 Lee Korea Asian 61 spotting vaginal introitus (11 o'clock) 2 WLE + laser none I negative 9 rec 9 m: WLE  +   +  NA NA NA NA NA 2006 Tjalma Belgium NA 55 bleeding posterior and anterior lower vaginal wall 4.5 PE none II negative 20 NED  +   +  NA NA NA - - 2012 Cormio Italy NA 59 discomfort, burning left posterior vestibule NA RV + LND chemo NA NA 54 DOD  +   +  NA NA NA NA NA 2012 Cormio Italy NA 42 none vulva 1 RV + LND none NA NA 39 NED  +   +  NA NA NA NA NA 2012 Karkouche France Caucasian 31 none bilateral labia minor NA WLE none NA NA 15 NED  +  - NA NA NA NA NA 2013 Wessel Belgium Caucasian 68 discharge, vulvar mass, pain posterior vaginal introitus 1.3 WLE none NA NA 25 NED  +   +   +  NA NA - - 2013 Musella Italy NA 57 vulvar mass, bleeding right labia major 5 RV + LND neoadjuvant chemo (PTX + CDDP) III positive 4 NED  +  -  +   +   +  - NA 2016 Sui China Asian 43 vulvar mass, itchy vaginal introitus 1.5 WLE chemo (PTX + CBDCA) I negative 24 NED -  +  NA NA  +  - - 2016 Tepeoglu Turkey NA 40 vulvar discomfort, bleeding left labia minor 2 WLE + LND none III positive 38 NED  +   +   +   +  NA NA NA 2017 Matsuzaki Japan Asian 68 vulvar mass vestibule 4 WLE none in situ negative 60 NED  +  - NA  +  NA NA NA 2017 Lee Korea Asian 64 vulvar mass, itchy right labia major 4 WLE none II negative 12 NED  +   +   +   +   +  NA NA 2017 He China NA 63 vulvar mass frenulum of labia minor 2 WLE none NA NA 26 NED  +   +   +   +  - - - 2019 Kurita Japan Asian 63 bleeding vestibule 2 WLE + LND RT I negative 12 NED  +  - NA  +  NA NA NA 2019 Kaltenecker USA African 53 vulvar mass, itchy, pain, discharge bilateral labia minor 6 WLE chemo (PTX + CBDCA) + RT IV positive 12 DOD  +  -  +  NA NA NA NA 2019 Ugwu Nigeria African 40 vulvar mass, bleeding, pain posterior lower vaginal wall 6 WLE CCRT I negative NA NED NA NA NA NA NA NA NA 2022 Moscoso Spain NA 66 itchy, discomfort left labia minor 2 WLE + LND none I negative 12 NED  +  -  +   +   +  - - 2022 Sabri USA NA 62 bleeding, dysuria, cramping right upper vaginal wall 3 none CCRT IV NA NA NED  +  -  +   +  - - - 2022 present case Japan Asian 63 vulvar mass posterior vulva (7 o'clock) 1 WLE none I negative 27 NED  +   +  NA  +   +  - - UK United Kingdam, USA United States of America, WLE Wide local excision, RV Radical vulvectomy, PE Pelvic exenteration, Chemo Chemotherapy, PTX Paclitaxel, CDDP Cisplatin, CBDCA Carboplatin, CCRT Concurrent chemoradiotherapy, RT Radiation therapy, LN Lymph node, NED No evidence of disease, DOD Died of disease, NA Not available Cases of intestinal-type adenocarcinoma of vulva and vagina UK United Kingdam, USA United States of America, WLE Wide local excision, RV Radical vulvectomy, PE Pelvic exenteration, Chemo Chemotherapy, PTX Paclitaxel, CDDP Cisplatin, CBDCA Carboplatin, CCRT Concurrent chemoradiotherapy, RT Radiation therapy, LN Lymph node, NED No evidence of disease, DOD Died of disease, NA Not available Intestinal-type neoplasms of the vagina were reported to be like the adenoma-carcinoma sequence in colorectal tumors [ 31 ]. However, intestinal-type neoplasms of the vulva are rarer, and the adenoma-adenocarcinoma sequence has not been discussed. There are no reports of genetic analysis of intestinal-type adenomas of the vulva, and there have been only few reports of genetic analysis of adenocarcinoma of intestinal-type of the vulva or intestinal-type adenomas/adenocarcinomas of the vagina. In the current case, which was a as a precancerous lesion diagnosed as tubulovillous adenoma with high-grade dysplasia of the vulva, genetic analysis was performed and high TMB was detected, accompanied by many cancer-associated gene mutations. This lesion may be in the process of carcinogenesis, and the genetic mutations may be related to malignant transformation. In the context of histopathological diagnosis considering tumor evolution, this case is very important. Adenocarcinoma of intestinal-type of the vulva resembles colorectal villous adenoma [ 32 ]. However, adenoma of intestinal-type of the vulva as a non-invasive, precancerous lesion has not been clearly defined. The tumor in the current case is an epithelial tumor with intestinal traits; following the classification of colorectal tumors, the most similar histomorphology is tubulovillous adenoma with high-grade dysplasia. Conventional colorectal adenoma recapitulates the normal crypt architecture of the mucosa in typical and early stage lesions, while some lesions also develop a villiform architecture. In the WHO classification, conventional colorectal adenoma is divided into tubular adenoma, tubulovillous adenoma, and villous adenoma depending on the ratio of tubular to villous structures [ 33 ]. Conventional colorectal adenoma is further divided into tumors with low-grade dysplasia and high-grade dysplasia [ 33 ]. Based on the context of colorectal adenoma, this case was diagnosed as tubulovillous adenoma with high-grade dysplasia. Fox et al. first reported a vaginal intestinal-type adenoma in 1988 [ 6 ]. Vitrey et al. reported low-grade adenoma of the vulva in 2003 [ 34 ]. In 2012, Karakouch et al. reported multiple tubulovillous adenomas of the vulva, including adenocarcinoma [ 19 ]. However, our report is the first case of tubulovillous adenoma with high-grade dysplasia that is expansile in the direction of the mucosa. We reviewed previous reports of adenocarcinoma of intestinal-type of the vulva, and the report by Willén et al. is likely a villous adenoma with an uncertain degree of dysplasia in the context of a colorectal adenoma [ 10 ]. Matsuzaki et al. reported villoglandular adenocarcinoma of the vulva without stromal invasion [ 24 ], which could also be considered tubulovillous adenoma with high-grade dysplasia. The cases of adenocarcinoma of intestinal-type of the vulva are considered to have a good prognosis, but it may be possible to redefine some of them as “adenoma.” IHC plays an important role in diagnosis. It is necessary to exclude metastatic gastrointestinal cancers, such as metastatic colorectal cancer. Typically, normal intestinal epithelium is CK7 negative, CK20 positive, and CDX2 positive. Most colorectal cancers are CK7 negative, CK20 positive, and CDX2 positive, while rectal cancers tend to be CK7 positive [ 35 ]. The present case was also CK7-positive. In previous reports, among the 21 cases in which IHC for CK20 and CK7 were performed, 20 cases (95%) were positive for CK20 and 13 cases (62%) were positive for CK7 (Table 2 ). CDX2 is expressed in the mucosal epithelium from the duodenum to the rectum and is also positive in intestinal-type neoplasms of the lower female genital tract. In previous reports, IHC for CDX2 was positive in all eight cases in which it was performed (Table 2 ). ER and PgR were mostly negative, as observed in the present case (Table 2 ). Notably, p16 was positive in the present case. Five other cases had IHC findings for p16, four cases of which were positive (Table 2 ). In another report, reverse transcription polymerase chain reaction for HPV in p16-positive adenocarcinoma of intestinal-type of the vulva did not detect HPV type 16, but only low-risk HPV [ 29 ]. HPV was negative in the present case. The significance of HPV status is unclear and further study is needed. In the present case, p53 staining was null, which may reflect the TP53 mutation described below. The surgical technique for intestinal-type neoplasms of the vulva has not been established; however, complete resection with sufficient margin is presumed to be important. Although there is one report of a patient who received neoadjuvant chemotherapy followed by surgery [ 21 ], most cases are preceded by surgery (Table 2 ). The most common surgical techniques are wide local excision and radical vulvectomy, with lymph node dissection in some cases (Table 2 ). In the present case, the lesion was less than 2 cm grossly and there were no suspicious findings of lymph node or distant metastasis on imaging. Because the depth of invasion could not be accurately determined by biopsy, wide local excision was performed. There was a sufficient margin, and no adjuvant therapy was performed. For most other cases in which tumors were removed by surgery, adjuvant therapy was not used (Table 2 ). Notably, a variety of cancer-associated mutations were detected in the current case. TP53 , KEL , RB1 , RNF43 , and PTEN mutations showed high variant allele frequency and were considered clonal mutations. The variant allele frequencies for PIK3CA and GNAS mutations were very low and were considered to be subclonal mutations. In 2019, Shuangshoti et al. reported tubulovillous adenoma of the vagina with KRAS and APC mutations, despite the absence of high-grade dysplasia or adenocarcinoma [ 36 ]. This type of neoplasia may have accumulated cancer-associated genetic mutations in an early stage of evolution. In the gastrointestinal tract, except the colorectum, the histopathologic pattern of adenocarcinoma of intestinal-type is common in the esophagus [ 35 ], stomach [ 37 ], and duodenal papilla [ 38 ]. Outside of the gastrointestinal tract, adenocarcinoma of intestinal-type is most common in the sinuses and is the second most common histologic type of primary sinus cancer [ 39 ]. Rare cases of adenocarcinoma of intestinal-type of the tongue [ 40 ], gallbladder [ 41 ], lung [ 42 ], bladder [ 43 ], and ureter [ 44 ] as primary sites have been reported. In cancers with histopathology showing adenocarcinoma of intestinal-type, TP53 and KRAS mutations are often detected. TP53 mutations are particularly frequent in adenocarcinoma of intestinal-type of the stomach and primary sinus [ 39 , 45 ]. Among adenocarcinomas of intestinal-type of the duodenal papilla, TP53 and KRAS mutations were reported in approximately 40% of cases and RNF43 mutations in approximately 15% of cases [ 38 ]. Another study reported mutations in KRAS , PIK3CA, and SMAD4 [ 46 ]. In intraductal papillary mucinous neoplasms of the pancreas of the intestinal type, the frequency of KRAS mutations is approximately 50% [ 47 ]. There is also a report of adenocarcinoma of intestinal-type with KRAS mutation arising from a mature cystic teratoma of the ovary [ 48 ]. In contrast, KRAS and BRAF mutations are rare in adenocarcinomas of intestinal-type of the sinus [ 39 ]. The present case was a precancerous lesion and not treated with adjuvant therapy. However, if the patient was in an advanced stage or had a recurrence with malignant transformation, additional treatment options may have needed to be considered. Potentially actionable genetic mutations found in this case may help establish effective targeted therapy. Loss or activation mutations in PTEN activate the phosphoinositide 3-kinases (PI3K)/protein kinase B (AKT)/mammalian target of rapamycin (mTOR) pathway [ 49 ] and predict sensitivity to poly (ADP-ribose) polymerase (PARP) inhibitors [ 50 ]. PIK3CA mutation also activates the PI3K/AKT/mTOR pathway [ 49 ]. Therefore, depending on the course of the disease, the combination of mTOR inhibitors or PARP inhibitors may be considered. GNAS mutations activate ERK/MAPK signals [ 51 ]. In this case, a mitogen-activated protein kinase inhibitor may have been useful. In the present case, TMB was high, at 13 Mut/Mb. TMB is an indicator of response to immunotherapy [ 52 ]. The KEYNOTE-158 study showed that advanced solid tumors with TMB ≥ 10 were more likely to respond to pembrolizumab, an anti-PD-1 antibody [ 53 ]. If the patient had been in an advanced stage or had a recurrence with malignant transformation, an immune checkpoint inhibitor like pembrolizumab may have been a treatment option. Therefore, in intestinal-type neoplasms of the vulva, a gene panel test may be helpful to select treatment options. In addition, while present case was microsatellite stable, some reports have shown that microsatellite instability–high and mismatch repair deficiency is more frequent in gastric adenocarcinoma of intestinal-type [ 54 , 55 ], and microsatellite status and IHC for mismatch repair protein may also be checked in intestinal-type neoplasms of the vulva. In conclusion, here we report a case of tubulovillous adenoma with high-grade dysplasia of the vulva harboring multiple cancer-associated mutations and high TMB. In cases of intestinal-type neoplasms of the vulva, it may be helpful to check TMB and gene mutations for treatment selection.